跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,042 条关于
“p53(Y220C)”
全部
1,042
临床试验
626
药物
288
机构
3
资讯
125
去年
FDA Clears IND for Nutshell Therapeutics' Novel p53 Y220C Reactivator NTS071
2年前
Jacobio Completes First Patient Dosage of p53 Y220C Activator in Clinical Trial
2年前
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the US
5个月前
LG Chem Acquires Worldwide Rights to First-in-Class p53 Y220C Cancer Drug FMC-220
去年
Frontier Medicines Presents Breakthrough Data on FMC-220, First-in-Class p53 Y220C Activator for Cancer Treatment
8年前
PMV Pharma's Rezatapopt: First p53(Y220C) Stabilizer Shows Promise in Solid Tumors
2年前
Rezatapopt Shows Promise in Targeting Previously 'Undruggable' p53 Mutation in Advanced Solid Tumors
2年前
Foundation Medicine and PMV Pharma Partner to Develop Companion Diagnostic for Rezatapopt
6个月前
PMV Pharma's Rezatapopt Shows Promise in First-in-Human Study for TP53 Y220C-Mutated Solid Tumors
去年
PMV Pharma's Rezatapopt Demonstrates 33% Response Rate in Phase 2 Trial for TP53 Y220C Solid Tumors
第 1 页,共 13 页
上一页
下一页